On November 29, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, reported that it will host an investor webcast on Monday, December 12th, 2022 at 12:00 pm EST / 6:00 pm CET to comment clinical data scheduled to be presented at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and provide a corporate update for shareholders and the broader financial community (Press release, MaaT Pharma, NOV 29, 2022, View Source [SID1234624546]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webcast will feature clinical data presented in an oral format on December 10th at the conference with the Company’s lead candidate MaaT013 as salvage therapy in 81 patients with treatment-resistant gastrointestinal acute Graft-vs-host-Disease (GI aGvHD) enrolled in an Early Access Program (EAP) in France and a poster presentation detailing results from the Phase 1b clinical trial evaluating MaaT033 in patients with acute myeloid leukemia.
Webcast details:
Date/Time: Monday, December 12, 2022; 6:00 pm CET (expected to be approximately one hour in duration).
Registration: To register for the live webcast, please click here.
Speakers:
Hervé Affagard, CEO & co-founder of MaaT Pharma
Mohamad Mohty, Professor and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital (AP-HP) and Sorbonne University,
Florent Malard, Professor of Hematology, Saint Antoine Hospital (AP-HP) and Associate Professor, Sorbonne University
Emilie Plantamura, Head of clinical development at MaaT Pharma
The webcast will be held in English, with French subtitles. A live Q&A session will be available in French and English.
Replay: A replay will be made available on the Company’s website for at least 90 days.
About MaaT013
MaaT013 is a standardized, high-richness, high-diversity Microbiome Ecosystem TherapyTM containing ButycoreTM (group of bacterial genera known to produce immuno-regulatory metabolites). It aims to restore the symbiotic relationship between the patient’s functional gut microbiome and their immune system to correct the responsiveness and tolerance of immune functions and reduce steroid-resistant, gastrointestinal-predominant aGvHD. MaaT013 has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). MaaT013 is an off-the-shelf, healthy-multi-donors-derived product intended for acute, hospital use.
About MaaT033
MaaT033 is a standardized, high richness, oral Microbiome Ecosystem TherapyTM. It aims to restore the gut ecosystem to full functionality to improve clinical outcomes as well as to control adverse events related to conventional treatments for liquid tumors. The capsule formulation facilitates administration and allows the potential to treat larger patients’ populations while maintaining the high and consistent richness and diversity of microbial species, including anti-inflammatory ButycoreTM species. MaaT033 is an off-the-shelf, healthy-multi donors-derived oral product intended for ambulatory setting.